J&J Reports Promising Antibody Combo Results in Multiple Myeloma Trial

Johnson & Johnson shared results from its Phase II RedirecTT-1 trial evaluating Talvey (talquetamab) and Tecvayli (teclistamab) in relapsed/refractory multiple myeloma (r/r MM) patients with extramedullary disease (EMD). Among 90 participants, the combination achieved a 78.9% overall response rate (ORR), with over half reaching a complete response or better—significantly higher than historical rates below 40% for this group.

Responses were also strong in patients previously treated with BCMA CAR-T or anti-FcRH5 therapies. At 13.4 months median follow-up, 66.2% maintained their response, 61% were progression-free at one year, and 74.5% remained alive. The combo’s safety profile was manageable, with mostly low-grade CRS and ICANS. Optional monthly dosing may have improved tolerability. Results were consistent with the agents as monotherapies and were presented at the 2025 European Hematology Association Congress.

01-07-2025